| Accession |
PRJCA014919 |
| Title |
First-in-human, phase I study of KC1036, a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors. |
| Relevance |
Medical |
| Data types |
PK analyses
|
| Organisms |
Homo sapiens
|
| Description |
KC1036 is a novel and selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, metastasis and drug resistance by inhibiting receptor tyrosine kinases (AXLs and VEGFRs) involved in the tumor microenvironment. This phase I, first-in-human study of KC1036 (NCT04387916) enrolled adult patients with advanced or metastatic solid tumors. This study was comprised of dose escalation (Part A: With the accelerated titration of the 10 mg QD, in which only one patient was enrolled, a standard 3+3 design was applied for 20, 40, 60, and 80 mg QD)followed by dose expansion (Part B) and recommended phase II dose (RP2D) expansion (Part C). |
| Sample scope |
plasma concentration |
| Release date |
2023-06-02 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| No funding support
|
|
|
|
|
|
| Submitter |
Yongsheng
Wang (wangys@wchscu.cn)
|
| Organization |
West China Hospital of Sichuan University |
| Submission date |
2023-02-13 |
